Standout Papers

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer 2004 2026 2011 2018 3.5k
  1. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer (2004)
    Massimo Cristofanilli, G. Thomas Budd et al. New England Journal of Medicine
  2. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer (2008)
    Cornelia Liedtke, Chafika Mazouni et al. Journal of Clinical Oncology
  3. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (2005)
    Roman Rouzier, Charles M. Perou et al. Clinical Cancer Research
  4. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (2016)
    Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology
  5. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (2015)
    Nicholas C. Turner, Jungsil Ro et al. New England Journal of Medicine
  6. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System (2007)
    Sabine Riethdorf, Herbert A. Fritsche et al. Clinical Cancer Research
  7. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer (2005)
    Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology
  8. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer (2005)
    Massimo Cristofanilli, Daniel F. Hayes et al. Journal of Clinical Oncology
  9. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival (2006)
    Daniel F. Hayes, Massimo Cristofanilli et al. Clinical Cancer Research
  10. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018)
    Nicholas C. Turner, Dennis J. Slamon et al. New England Journal of Medicine
  11. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer (2006)
    G. Thomas Budd, Massimo Cristofanilli et al. Clinical Cancer Research
  12. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer (2016)
    Charlotte Fribbens, Ben O’Leary et al. Journal of Clinical Oncology
  13. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial (2018)
    Ben O’Leary, Rosalind Cutts et al. Cancer Discovery
  14. The Landscape of Targeted Therapies in TNBC (2020)
    Elena Vagia, Devalingam Mahalingam et al. Cancers
  15. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019)
    Nicholas C. Turner, Yuan Liu et al. Journal of Clinical Oncology
  16. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives (2022)
    Eleonora Nicolò, Federica Giugliano et al. Cancer Treatment Reviews
  17. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022)
    Massimo Cristofanilli, Hope S. Rugo et al. Clinical Cancer Research

Immediate Impact

2 by Nobel laureates 16 from Science/Nature 159 standout
Sub-graph 1 of 17

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
92 intermediate papers

Works of Massimo Cristofanilli being referenced

Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer
2019
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
2005 Standout
and 52 more

Author Peers

Author Last Decade Papers Cites
Massimo Cristofanilli 25726 18181 11443 589 37.3k
Klaus Pantel 29500 27624 12326 709 52.8k
Fabrice André 19923 13758 12659 667 36.8k
Daniel F. Hayes 25941 20441 9264 407 45.3k
Nadia Harbeck 19898 12822 11633 839 32.4k
Eric P. Winer 35888 19716 13979 730 55.0k
Daniel D. Von Hoff 23213 8189 6568 816 43.9k
Charles Swanton 12369 12292 8250 314 29.4k
José Baselga 25287 9567 13824 482 45.7k
Robert S. Kerbel 16351 13246 5745 398 41.1k
Hope S. Rugo 30324 11168 15990 833 43.5k

All Works

Loading papers...

Rankless by CCL
2026